Cargando…

1307. Emerging Treatments in Ongoing Battle Against Community-Acquired Bacterial Pneumonia (CABP): The Positive Impact of Online Education

BACKGROUND: The leading infectious cause of hospitalization and infection-related mortality, pneumonia imparts a significant, but often underappreciated, burden. Agents in the antibiotic pipeline have the potential to improve both individual and public health, as well as support antibiotic stewardsh...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hurst, Simi, Smith, Susan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252573/ http://dx.doi.org/10.1093/ofid/ofy210.1140

Ejemplares similares

Efficacy of Delafloxacin versus Moxifloxacin against Bacterial Respiratory Pathogens in Adults with Community-Acquired Bacterial Pneumonia (CABP): Microbiology Results from the Delafloxacin Phase 3 CABP Trial
por: McCurdy, Sandra, et al.
Publicado: (2020)

A Phase 3 Study to Compare Delafloxacin With Moxifloxacin for the Treatment of Adults With Community-Acquired Bacterial Pneumonia (DEFINE-CABP)
por: Horcajada, Juan P, et al.
Publicado: (2019)

2230. Analysis of the Microbiological Data from the Delafloxacin (DLX) Phase 3 Community-acquired Bacterial Pneumonia (CABP) Trial
por: McCurdy, Sandra, et al.
Publicado: (2019)

Serotype distribution and antimicrobial susceptibility of Streptococcus pneumoniae isolates from a Phase III community-acquired bacterial pneumonia (CABP) trial
por: McCurdy, S P, et al.
Publicado: (2021)

In Vitro Activity of Lefamulin Against a Global Collection of Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP, SENTRY 2015)
por: Paukner, Susanne, et al.
Publicado: (2017)

Community-Acquired Pneumonia: An Unfinished Battle
por: Nair, Girish B., et al.
Publicado: (2011)

2234. Outcomes by Age and Gender from a Global Phase 3 Study of Delafloxacin (DLX) in Community-Acquired Bacterial Pneumonia (CABP)
por: Madej, Andrzej, et al.
Publicado: (2019)

2232. A Global Phase 3 Study of Delafloxacin (DLX) Compared with Moxifloxacin (MOX) in Patients with Community-acquired Bacterial Pneumonia (CABP)
por: Salata, Robert, et al.
Publicado: (2019)

Antibiotic prescribing by age, sex, race, and ethnicity for patients admitted to the hospital with community-acquired bacterial pneumonia (CABP) in the All of Us database
por: Gilmore, Corbyn M., et al.
Publicado: (2023)

2228. Treatment of Community-Acquired Bacterial Pneumonia (CABP) in Patients with Diabetes: Outcomes from a Global Phase 3 Study of Delafloxacin (DLX)
por: Kaidashev, Igor, et al.
Publicado: (2019)

1307. The Mycoplasma Conundrum
por: Rand, Kenneth
Publicado: (2021)

LB6. Oral Lefamulin Is Safe and Effective in the Treatment of Adults With Community-Acquired Bacterial Pneumonia (CABP): Results of Lefamulin Evaluation Against Pneumonia (LEAP 2) Study
por: Alexander, Elizabeth, et al.
Publicado: (2018)

1353. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Commonly Causing Community-Acquired Bacterial Pneumonia (CABP): 2016 SENTRY Data From the United States
por: Paukner, Susanne, et al.
Publicado: (2018)

703. In Vitro Activity of Lefamulin Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2017–2018 Results From the United States (US)
por: Sader, Helio S, et al.
Publicado: (2019)

Lack of CaBP1/Caldendrin or CaBP2 Leads to Altered Ganglion Cell Responses
por: Sinha, Raunak, et al.
Publicado: (2016)

Commentary: COVID-19-associated mucormycosis: The ongoing battle
por: Nair, Akshay Gopinathan
Publicado: (2021)

684. Cardiac Safety in Adults with Community-Acquired Bacterial Pneumonia (CABP) Treated with Lefamulin (LEF) or Moxifloxacin (MOX): Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Darpo, Borje, et al.
Publicado: (2019)

Membrane targeting of the EF-hand containing calcium-sensing proteins CaBP7 and CaBP8
por: McCue, Hannah V., et al.
Publicado: (2009)

1365. In Vitro Activity of Lefamulin (LEF) Against Bacterial Pathogens Causing Community-Acquired Bacterial Pneumonia (CABP): SENTRY Surveillance 2016 Results From Asia-Pacific (APAC) and Latin America (LA)
por: Paukner, Susanne, et al.
Publicado: (2018)

699. Hepatobiliary Safety in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Lewis, James H, et al.
Publicado: (2019)

2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

594. The Prevention and Management of HIV: Online Education as a Tool to Improve Knowledge and Confidence Among HIV/ID Specialists
por: Hurst, Simi, et al.
Publicado: (2018)

1325. HIV, Aging, and Comorbid Conditions: Case-Based, Online Education Improves HIV/ID Specialists’ Management Strategies
por: Hurst, Simi, et al.
Publicado: (2018)

The ongoing battle to address respiratory health in people experiencing homelessness
por: Burki, Talha Khan
Publicado: (2022)

Malaria in the horn of Africa: The ongoing battle against drug resistance
por: Platon, Lucien, et al.
Publicado: (2023)

2386. Efficacy of Lefamulin (LEF) vs. Moxifloxacin (MOX) Against Common Pathogens in Adults With Community-Acquired Bacterial Pneumonia (CABP): Results From the Phase 3 Lefamulin Evaluation Against Pneumonia (LEAP 1) Study
por: File, Thomas, et al.
Publicado: (2018)

Determination of the Membrane Topology of the Small EF-Hand Ca(2+)-Sensing Proteins CaBP7 and CaBP8
por: McCue, Hannah V., et al.
Publicado: (2011)

2233. Efficacy and Symptom Resolution by Visit in Adults With Community-Acquired Bacterial Pneumonia (CABP) Treated With Lefamulin (LEF) or Moxifloxacin (MOX): Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Results
por: Schranz, Jennifer, et al.
Publicado: (2019)

Pluto confidential: an insider account of the ongoing battles over the status of Pluto
por: Maran, Stephen, et al.
Publicado: (2014)

Interferon-induced ISG15 pathway: an ongoing virus–host battle
por: Zhao, Chen, et al.
Publicado: (2013)

English society in the early middle ages, (1066-1307) /
por: Stenton, Doris Mary
Publicado: (1981)

Decalmodulation of Ca(v)1 channels by CaBPs
por: Hardie, Jason, et al.
Publicado: (2015)

NAC Transcription Factors as Positive or Negative Regulators during Ongoing Battle between Pathogens and Our Food Crops
por: Bian, Zhiyuan, et al.
Publicado: (2020)

China’s ongoing battle against the coronavirus: a scholar-practitioner's experiences and reflections
por: Wang, Yuncai
Publicado: (2020)

Virtual Patient Simulation in HIV: An Online Educational Tool to Improve Evidence-Based Clinical Decision-Making
por: Hurst, Simi, et al.
Publicado: (2017)

2245. Oral 5-Day Lefamulin for Outpatient Management of Pneumonia Outcomes Research Team (PORT) Risk Class III/IV Community-Acquired Bacterial Pneumonia (CABP): Post Hoc Analysis of the Lefamulin Evaluation Against Pneumonia (LEAP) 2 Phase 3 Study
por: Schranz, Jennifer, et al.
Publicado: (2019)

664. Efficacy in Adults With Moderate to Severe Community-Acquired Bacterial Pneumonia (CABP) and Pneumonia Outcomes Research Team (PORT) Risk Class III to V: Results of a Pooled Analysis of Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Study Outcomes
por: Alexander, Elizabeth, et al.
Publicado: (2019)

Evolution and functional diversity of the Calcium Binding Proteins (CaBPs)
por: Haynes, Lee P., et al.
Publicado: (2012)

2017. Improving Timely Diagnosis of Meningitis and Encephalitis: The Effectiveness of Online CME
por: Hurst, Simi, et al.
Publicado: (2018)

663. Efficacy and Safety of Lefamulin (LEF) vs. Moxifloxacin (MOX) for Legionella pneumophila (LP) in Patients with Community-Acquired Bacterial Pneumonia (CABP): Pooled Results From the Lefamulin Evaluation Against Pneumonia (LEAP) 1 and LEAP 2 Phase 3 Clinical Trials
por: Shorr, Andrew F, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_lj2m2315fg57h1ra9ano4anvk0